105 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
7
Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.
Sichuan University
15
Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation.
The University of Georgia
25
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina at Chapel Hill
3
Diamidine compounds for selective inhibition of protein arginine methyltransferase 1.
The University of Georgia
6
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
11
Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents.
Georgia State University
25
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
Sun Yat-Sen University
55
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design.
Tango Therapeutics
27
Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities.
Gannan Medical University
36
An update on small molecule compounds targeting synthetic lethality for cancer therapy.
Sichuan University
4
Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader.
Icahn School of Medicine at Mount Sinai
28
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
Amgen
64
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
Tango Therapeutics
1
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity.
Insilico Medicine Shanghai Ltd
32
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors.
Ocean University of China
11
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
1
PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
2
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
GlaxoSmithKline
5
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
University of Toronto
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
34
Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation.
University of Jinan
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
12
An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor.
Purdue University
31
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
28
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.
AstraZeneca
48
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers.
Tango Therapeutics
34
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma.
Zhejiang Sci-Tech University
36
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors.
University of Chinese Academy of Sciences
61
Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.
China Pharmaceutical University
9
Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies.
First Affiliated Hospital of Gannan Medical University
44
Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
Shandong University
24
Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy.
East China Normal University
12
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
Sun Yat-Sen University
27
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
17
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
47
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
24
Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
Sichuan University
45
Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy.
Shanghai Institute of Materia Medica
38
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Sun Yat-Sen University
24
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Institut De G£N£Tique Et De Biologie Mol£Culaire Et Cellulaire
61
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
Csir-Indian Institute of Chemical Biology
11
Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.
Novartis Institutes For Biomedical Research
15
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Mirati Therapeutics
35
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Mirati Therapeutics
27
Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
China Pharmaceutical University
33
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
The Broad Institute of Mit and Harvard
44
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
33
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
Merck
17
A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.
Janssen Pharmaceutica
26
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
University of Michigan Medical School
16
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.
Epizyme
15
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
University College London
25
Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.
University of Toronto
7
Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.
Punjabi University
46
Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia.
Chinese Academy of Sciences
42
Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Prelude Therapeutics
1
The development and characterization of a chemical probe targeting PRMT1 over PRMT5.
University of North Florida
37
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
University of Jinan
6
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.
Prelude Therapeutics
10
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Sun Yat-Sen University
2
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Lilly Research Laboratories
18
Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation.
Zhejiang Sci-Tech University
31
MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR
Ocean University of China
135
TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS
Janssen Pharmaceutica
47
4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof
Yangtze River Pharmaceutical Group Co.
155
Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
Proximagen
12
JAK inhibitors containing a 4-membered heterocyclic amide
Theravance Biopharma R&D Ip
155
Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
Proximagen
182
Kappa opioid receptor antagonists and products and methods related thereto
Blackthorn Therapeutics
5
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
University of Georgia
12
Novel inhibitor of bacterial sphingomyelinase, SMY-540, developed based on three-dimensional structure analysis.
Tokushima Bunri University
93
Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
Bristol Myers Squibb
1
Electrostatic Interactions as Mediators in the Allosteric Activation of Protein Kinase A RIa.
University of California San Diego
2
Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1.
University of Iowa
5
Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
Research Triangle Institute